key: cord-0839026-881lu3zk
authors: Simon, David; Fagni, Filippo; Tascilar, Koray; Schett, Georg
title: Response to: “Low levels of anti‐SARS‐CoV‐2 antibodies after vaccination in rituximab‐ treated patients: Comment on article of Simon et al”.
date: 2021-11-01
journal: Arthritis Rheumatol
DOI: 10.1002/art.42012
sha: e0867c9532abb2fc4555fb91c613abe4b292d8f4
doc_id: 839026
cord_uid: 881lu3zk

nan

We read with great interest the comment of Evangelatos et al (1) on our study on SARS-CoV-2 vaccine responses in rituximab-treated patients (2) . The authors briefly reviewed current evidence on the reduced response rates to SARS-CoV-2 vaccines amongst patients undergoing B-cell depletion with rituximab (RTX) and provided novel data on this topic. In a series of 11 patients with immunemediated inflammatory diseases (IMIDs) treated with RTX, only 2 developed detectable IgG against SARS-CoV-2 spike protein after SARS-CoV-2 mRNA BNT162b2 vaccination. This finding supports observations from other studies including our study (1, 2, 5, 6) , in which we showed that humoral but not T-cell-mediated responses to SARS-CoV-2 vaccination are reduced in RTX treated patients (2) .

These findings are highly relevant to the estimated 700,000 patients with hematologic malignancies This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.42012 benefit from additional boosters to achieve a protective humoral response (9) . In this context, the observation that SARS-CoV-2 infection can mobilize tissue B cells and trigger protective antibody formation in RTX-treated patients without peripheral B cells (2) , is interesting and may support the use of booster vaccinations. Hence, fast booster vaccinations as well cross-vaccinations switch agents may provide the possibility for mobilizing a humoral immune response when the standard regimen has failed.

Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab-treated patients: Comment on article of Simon et al. Arthritis Rheumatol

Brief Report: Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in B cell depleted autoimmune patients

MabThera recommended for approval in rheumatoid arhritis in Europe

FDA approves Roche's Rituxan (rituximab) in children with two rare blood vessel disorders

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1

Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response Ann Rheum Dis

This article is protected by copyright. All rights reserved.